Ferritin and prolactin levels in multiple sclerosis

Israel Medical Association Journal

Volumn 13, Issue 2, 2011, Pages 91-95

  da Costa, Rafael ^a,b   Szyper Kravitz, Martine ^a,e   Szekanecz, Zoltan ^c   Csépány, Tünde ^c   Dankó, Katalin ^c   Shapira, Yinon ^a   Zandman Goddard, Gisele ^d,e   Orbach, Hedi ^d,e   Agmon Levin, Nancy ^a,e   Shoenfeld, Yehuda ^a,e  

^a SHEBA MEDICAL CENTER   (Israel)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c UNIVERSITY OF DEBRECEN   (Hungary)

^d WOLFSON MEDICAL CENTER   (Israel)

^e TEL AVIV UNIVERSITY   (Israel)

Author keywords

Autoimmunity; Ferritin; Iron; Multiple sclerosis; Prolactin

Indexed keywords

BIOLOGICAL MARKER; FERRITIN; PROLACTIN;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; HYPERFERRITINEMIA; HYPERPROLACTINEMIA; MALE; MULTIPLE SCLEROSIS; PROLACTIN BLOOD LEVEL; SEX DIFFERENCE;

ADULT; BIOLOGICAL MARKERS; FEMALE; FERRITINS; HUMANS; HYPERPROLACTINEMIA; INCIDENCE; IRON METABOLISM DISORDERS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROLACTIN;

EID: 79952403536     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Miller JR. Multiple sclerosis. In Rowland LP, ed. Merrit's Neurology. 3rd edn. Philadelphia: Lippincott-Williams & Wilkins, 2000: 773-91.
2. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50 (1): 121-7.
3. Weiner HL. MS is an inflammatory T cell mediated autoimmune disease. Arch Neurol 2004; 61 (10): 1613-15.
4. Roach ES. Is multiple sclerosis an autoimmune disorder? Arch Neurol 2004; 61 (10): 1625-6.
5. Grau-López L, Raïch D, Ramo-Tello C, et al. Myelin peptides in multiple sclerosis. Autoimmun Rev 2009; 8 (8): 650-3
6. Shoenfeld Y, Blank M, Abu-Shakra M, et al. The mosaic of autoimmunity: prediction, autoantibodies, and therapy in autoimmune diseases - 2008. IMAJ Isr Med Assoc J 2008; 10: 13-19.
7. Shoenfeld Y, Zandman-Goddard G, Stojanovich L, et al. The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases - 2008. IMAJ Isr Med Assoc J 2008; 10: 8-12.
8. Shoenfeld Y, Gilburd B, Abu-Shakra M. O, et al. The mosaic of autoimmunity: genetic factors involved in autoimmune diseases. IMAJ Isr Med Assoc J 2008; 10: 3-7.
9. Chikanza ZC. Prolactin and neuroimmunomodulation: in vitro and in vivo observations. Ann NY Acad Sci 1999; 876: 119-30.
10. Heesen C, Gold SM, Bruhn M, Mönch A, Schulz KH. Prolactin stimulation in multiple sclerosis: an indicator of disease subtypes and activity. Endocr Res 2002; 28 (1-2): 9-18.
11. Walton PE, Cronin MJ. TNF-α and INF-γ reduce prolactin release in vitro. Am J Physiol 1990; 259: E672-6.
12. Orbach H, Shoenfeld Y. Hyperprolactinemia and autoimmune diseases. Autoimmun Rev 2007; 6: 537-42.
13. Jara LJ, Benitez G, Medina G. Prolactin, dendritic cells and systemic lupus erythematosus. Autoimmun Rev 2008; 7 (3): 251-5.
14. Zandman-Goddard G, Shoenfeld Y. Hyperferritinemia in autoimmunity - 2008. IMAJ Isr Med Assoc J 2008; 10: 83-4.
15. Levine SM, Chakrabarty A. The role of iron in the pathogenesis of experimental allergic encephalomyelitis and multiple sclerosis. Ann N Y Acad Sci 2004; 1012: 252-66.
16. Zandman-Goddard G, Shoenfeld Y. Ferritin in autoimmune diseases. Autoimmun Rev 2007; 6: 457-63.
17. Orbach H, Zandman-Goddard G, Amital H, et al. Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Ann N Y Acad Sci 2007; 1109: 385-400.
18. Kira J, Harada M, Yamaguchi Y, Shida N, Goto I. Hyperprolactinemia in multiple sclerosis. J Neurol Sci 1991; 102: 61-6.
19. Azar ST, Yamout B. Prolactin secretion is increased in patients with multiple sclerosis. Endocr Res 1999; 25: 207-14.
20. Yamasaki K, Horiuchi I, Minohara M, et al. Hyperprolactinemia in opticospinal multiple sclerosis. Intern Med 2000; 39 (4): 296-9
21. Then Bergh F, Kuemple T, Schumann E, et al. Monthly i.v. methylprednisolone in relapsing-remitting MS: reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations. BMC Neurol 2006; 6: 19-28.
22. Wei T, Lightman SL. The neuroendocrine axis in patients with multiple sclerosis. Brain 1997; 120: 1067-76.
23. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005; 128: 2705-12.
24. Hulek SW, Power S, Connor Jr. Distribution of transferrin and ferritin binding in normal and multiple sclerosis human brains. J Neurol Sci 1999; 165 (1): 48-55.
25. Fagos C, Makis AC, Chaidos A, et al. Serum ferritin, transferrin and soluble transferrin receptor levels in multiple sclerosis patients. Mult Scler 2005; 11(3): 272-5.